



Press release

EIPICO seeks to provide the latest technology for drug production in the world in the Sudan plant.

The export of "Remaist - Remdesivir " product to Iraq and the Kurdistan region, and the export is underway to Uganda.

We succeeded in opening new markets in the Far East region.

We are about to complete the registration of 7 Biosimilars & Biologicals products for the treatment of tumors, rheumatoid and chronic diseases in preparation for making them available to citizens by the end of this year.

Tenth of Ramadan on May 25, 2021

Dr. Ahmed Kelani, Chairman and Managing Director of the Egyptian International Company for Pharmaceutical Industries (EIPICO) - the largest subsidiary of ACDIMA Pharmaceuticals Company - stated that within the framework of the strategic direction of the state to provide the necessary medicines to the sisterly State of Sudan and in implementation of our vision to develop the traditional export policies and pattern, through expansion In joint manufacturing projects in several countries, in line with the countries 'idea of resettling pharmaceutical industries in them, and not to lose these markets in the future.

Recently in Sudan, a partnership contract in the field of drug manufacturing was signed with the Sudanese Kambal Company, in the presence of the Sudanese Minister of Health Dr. Omar Muhammad Al-Najeeb and members of the Egyptian Embassy in Khartoum, to establish a drug factory in Soba for joint manufacture of EIPICO drugs, the project capital is 30 million dollars, Equally, between EIPICO and Kambal, all studies have been completed and construction has begun, and it is planned that within two years from now the construction of the factory will be completed, which is a strategic partnership to reach drug manufacturing at a rate of more than 70%, and upon signature, technical committees were formed. To choose production lines for different production areas, with a focus on the selection of the latest technology available in the world and also with high production capacities to meet the needs of targeted production and marketing plans in the short and medium-term, and the factory will contribute to meeting Sudan's needs of many medicines from pharmaceutical groups A variety of different pharmaceutical forms (drops - ampoules - syrups - tablets and others), and it will also be a starting point for the export of the company's products to the Neighboring countries.



Egyptian International Pharmaceutical Industries Company – EIPICO

Yes, We Care

Press release

Regarding the company's role, and in cooperation with ACDIMA, EIPICO was keen to support the efforts of the state represented by the Egyptian Ministry of Health and the Egyptian Medicines Authority in confronting the Covid-19 epidemic, by providing millions of units of many medicines used in treatment protocols, and the company also succeeded in producing The latest international medicine, as it produced (Epifluvir-Favipiravir200), known internationally as Avigan, (Remaist), known internationally as Remdesivir. The company has fulfilled its duty towards the citizens, as the production processes of all the company's medicines have not been affected to ensure a safe strategic stock of these medicines and raw materials in anticipation of any global emergency due to the Corona epidemic. This year it also succeeded in exporting the Remaist product "Remdesivir" to both Iraq and the region. Kurdistan, in addition to other shipments, is being prepared for export to Uganda.

It is worth noting that EIPICO's pharmaceutical exports amounted to 177.8 million EGP in the first quarter of this year, achieving a growth of 33% compared to the same period of the previous year. The company also succeeded this year in expanding in the Far East region and opening new markets in Brunei and Cambodia. EIPICO ranks first in drug exports, with 23% of Egypt's total medicine exports to 69 countries.

Dr. Kelani added that the company achieved good performance rates in the first quarter of this year (January - March 2021), as it achieved production of 821 million EGP and sales of 798 million EGP, an increase of 8% over sales for the same period last year.

According to IQVIA data, the company has achieved second place in the local market in terms of the number of packages sold, with an acquisition ratio of 6.7% of the volume of sold units, while it has achieved seventh place in terms of sales value in the local market, at a rate of 3% in terms of sales value (This is because the average selling price per unit of EIPICO products is considered one of the lowest prices while adhering to the highest quality levels at the same time). Along the same lines, EIPICO Ophthalmic products achieved first place in terms of the number of sold units in the local market in March of this year, with an acquisition rate of 23% Market share. It is ranked fourth in terms of the value of sales by 8% Market share.

On the developments of the EIPICO 3 project for the production of Biosimilars & Biologicals, Dr. Ahmed Kelani announced that EIPICO is currently in the process of putting the final touches towards the actual start of the project, whose investments exceed 1.2 billion EGP, both at the level of civil construction in the factory land in Tenth of Ramadan City. And also at the level of implementing the factory abroad according to the latest international modular construction methods and moving it ready for installation with us, and we are about to complete the registration of 7 products for the treatment of tumors, rheumatoid and chronic diseases, with different concentrations of these products, to start the production of these drugs In the first phase of the BULK system, to provide it to citizens by the end of this year, until the implementation of the EIPICO 3 plant is completed.



Egyptian International Pharmaceutical Industries Company – EIPICO

Yes, We Care

Press release

Dr. Kelani concluded by pointing out that despite the unprecedented crisis witnessed in the past year in the world and Egypt with the spread of the Corona epidemic, EIPICO has managed to implement its plans to modernize and develop its technical capabilities through the implementation of investments of more than 300 million EGP to develop production lines and establish sections New productivity and laboratories with the modernization of the company's infrastructure.

In this year, the establishment, preparation, and licensing of the Penems area were completed to produce this modern generation of antibiotics, Penems. EIPICO is the only one in Egypt that has an independent area for the production of these drugs according to the latest levels of technology in the world, with a production capacity of 100,000 vials per day.

About the Egyptian International Pharmaceutical Industries Company - EIPICO

EIPICO was established in the city of Tenth of Ramadan in 1980 with a capital of 7 million Egyptian pounds that has now been increased to 1500 million EGP as an Egyptian joint stock company operating following the investment law and registered in the Egyptian Stock Exchange since 1995 under the code **(PHAR.CA)**. EIPICO started production in 1985 as a pioneer in the pharmaceutical industry in Egypt according to Good Manufacturing Practices rules.

EIPICO has two factories built on an area of 120,000 square meters, with 9 sterile areas being the largest and most advanced in Egypt and the MENA region and the first center for biotechnology and genetic engineering research to manufacturing biological preparations.

EIPICO manufactures more than 400 pharmaceutical products covering 25 therapeutic groups, as EIPICO ranks first in the Egyptian ophthalmology market by units and is the leading company in the export of Egyptian medicines as its products are exported to more than 69 countries around the world with a market share of 23% of Total Egyptian pharmaceutical exports

For more information, please visit our official website <https://www.eipico.com.eg>

To communicate :

Abdel-Raheem Ghareeb

Investor Relations Manager

Tenth of Ramadan - First Industrial Zone - B1

Tel: 055499199

Fax: 055499306

a.elmoraly@eipico.net

###